BioCryst Pharma (BCRX) Misses Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.65 --0%
Revenue Growth %: +13.7%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
PKE, LNN, More
Revenue Growth %: +13.7%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
PKE, LNN, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $3.77 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
- Waste stocks ride AI and healthcare boom as CLH surges 27%
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
